Alexion's hypophosphatasia drugs wins breakthrough status

05/29/2013 | MedicalDaily.com

The FDA awarded breakthrough therapy designation to Alexion Pharmaceuticals' asfotase alfa as a treatment for perinatal-, infantile- and juvenile-onset forms of hypophosphatasia. Asfotase alfa is an enzyme replacement therapy designed to treat, prevent and reverse the complications of hypophosphatasia.

View Full Article in:

MedicalDaily.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX